Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis

Current Medical Research and Opinion
Michael E ThaseKaren A Tourian

Abstract

To evaluate the effect of the serotonin-norepinephrine re-uptake inhibitor desvenlafaxine on blood pressure and incidence of new onset hypertension in pooled short-term studies and in two longer-term, randomized withdrawal studies. Data from patients randomly assigned to desvenlafaxine 10 mg to 400 mg/day or placebo in 11 short-term (8-12 weeks), fixed-dose, double-blind, placebo-controlled studies of major depressive disorder (MDD) were pooled for analysis; two desvenlafaxine randomized withdrawal studies (36 and 46 weeks) were analyzed separately. www.clinicaltrials.gov , NCT00072774, NCT00073762, NCT00277823, NCT00300378, NCT00384033, NCT00798707, NCT00863798, NCT01121484, NCT00824291, NCT01432457, NCT00075257, NCT00887224. Outcomes included change from baseline in supine systolic blood pressure (SSBP) and supine diastolic blood pressure (SDBP), assessed using a mixed model repeated measures (MMRM) analysis, and incidence of hypertension (defined as three consecutive second SDBP measures ≥90 mm Hg AND increase of ≥10 mm Hg from baseline and/or SSBP ≥140 mm Hg AND increase of ≥10 mm Hg), analyzed using Cochran Mantel Hanzael tests. Potential predictors of change in SSBP and SDBP at LOCF were examined by including predictor va...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jan 1, 1989·Psychological Medicine. Monograph Supplement·S J WarringtonM Lader
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M E ThaseR L Rudolph
Jan 25, 2003·Journal of Clinical Psychopharmacology·Pierre V TranWilliam Z Potter
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Mar 2, 2005·Journal of Clinical Psychopharmacology·Michael E ThaseMichael J Detke
Sep 27, 2005·Journal of Women's Health·Michael E ThaseSusan G Kornstein
May 6, 2006·The Journal of Pharmacology and Experimental Therapeutics·Darlene C DeecherTerrance H Andree
May 3, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joachim WernickeFujun Wang
Oct 6, 2007·International Clinical Psychopharmacology·Lucia Septien-VelezKaren A Tourian
May 30, 2008·Current Medical Research and Opinion·Michael R LiebowitzKaren A Tourian
Aug 14, 2009·Journal of Affective Disorders·Raymond W LamUNKNOWN Canadian Network for Mood and Anxiety Treatments (CANMAT)
Jan 16, 2010·Journal of Clinical Psychopharmacology·Karl RickelsClaudine Brisard
Aug 27, 2011·Journal of Clinical Psychopharmacology·Boadie W DunlopChristine J Guico-Pabia
Nov 22, 2011·Expert Opinion on Pharmacotherapy·Chi-Un Pae

❮ Previous
Next ❯

Citations

Aug 16, 2016·The Psychiatric Clinics of North America·Joseph F Goldberg, Carrie L Ernst
Oct 7, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Seetal DoddMichael Berk

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.